



# Endo Investor Presentation

---

September 2024

# Cautionary Note Regarding Forward-Looking Statements

---

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, any statements relating to listing, uplisting, or trading on a national securities exchange, business plans, business growth, growth strategies, cash flow generation, commercial or manufacturing capabilities, intellectual property, litigation, product development, product pipeline, product launches and any other statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential," "target" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: timing of receipt of required approvals and satisfaction of other customary conditions for listing on a national securities exchange; timing or results of any potential future litigation, investigations, claims, actual or contingent liabilities; changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition such as those related to XIAFLEX®; the timing and uncertainty of the results of both the research and development and regulatory processes, including regulatory approvals; health care and cost containment reforms, including government pricing, tax and reimbursement policies litigation; the performance including the approval, introduction and consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; our ability to develop and expand our product pipeline and to continue to develop the market for XIAFLEX® and other branded, sterile injectable or unbranded products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of any business development and/or strategic priorities; uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and our ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission (the "SEC"), including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.

# Non-GAAP Financial Measures

---

This presentation may refer to non-GAAP financial measures, including, among others, adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”), adjusted net income, adjusted gross profit, adjusted gross margin and adjusted operating expenses that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and that may be different from non-GAAP financial measures used by other companies. Endo utilizes these financial measures because (i) they are used by Endo, along with financial measures in accordance with GAAP, to evaluate Endo’s operating performance; (ii) Endo believes that they will be used by certain investors to measure Endo’s operating results; (iii) the Compensation & Human Capital Committee of Endo’s Board of Directors uses adjusted EBITDA, or similar measures, in assessing the performance and compensation of substantially all of Endo’s employees, including executive officers. Endo believes that presenting these non-GAAP measures provides useful information about Endo’s performance across reporting periods on a consistent basis by excluding certain items, which may be favorable or unfavorable, pursuant to certain specified procedures. These non-GAAP measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. Endo’s definition of these non-GAAP measures may differ from similarly titled measures used by others. Refer to the Second Quarter Results slides for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric.



# Business Overview

---

# Endo emerged from its financial restructuring with strong cash flow generation, a focused portfolio and poised for growth



**Strong cash flow generation**

**Focused portfolio**

**Poised for growth**

[a] Endo, Inc. acquired substantially all of EIP's assets through the Chapter 11 process, free and clear of material legacy liabilities

# Endo has an unencumbered balance sheet and is free of legacy overhangs

		Pre-Emergence		June 30, 2024
<b>Funded Indebtedness</b>	Significantly <b>lower funded debt</b>	> \$8.0B	>	\$2.5B
<b>Net Leverage</b>	Meaningful <b>improvement in net leverage</b>	> 10.0x	>	~3.5x
<b>Interest Payments</b>	<b>Lower annual interest</b> payments	> \$500M	>	~\$230M
<b>Litigation &amp; Tax Uncertainties</b>	<b>Elimination of overhang</b> and related cost	Multiple	>	Resolved in Bankruptcy

# Endo has a strong foundation to drive growth

---

~180

Products Available  
to Patients and Providers

---

2.6M

Prescriptions Dispensed  
Each Month

---

60+

Products in  
Pipeline

---

~225K

US Patients Treated  
with XIAFLEX<sup>®</sup>

---

>95%

U.S. Hospitals Using  
Endo Products

---

~3,000

Global  
Team Members

---

# Endo operates across four businesses

## GROWTH BUSINESSES

2023: \$1,289M | 64% | 48%  
 1H'24: \$ 615M | 71% | 50%



### Branded Pharmaceuticals

Innovative therapies for certain specialty areas



### Sterile Injectables

Critical medicines for hospitals

2023: \$859M | 43% | 53%  
 1H'24: \$426M | 49% | 57%

\$430M | 21% | 37%  
 \$189M | 22% | 33%

## ESTABLISHED BUSINESSES

2023: \$723M | 36% | 35%  
 1H'24: \$251M | 29% | 26%



### Generic Pharmaceuticals

High-quality low-cost medicines



### International Pharmaceuticals

Innovative medicines for Canadian market

\$650M | 32% | 37%  
 \$213M | 25% | 27%

\$73M | 4% | 23%  
 \$38M | 4% | 23%

REVENUE | % REVENUE | OPERATING MARGIN % [a]

[a] Operating margin % is calculated as segment adjusted income from continuing operations before income taxes divided by segment revenues. Segment adjusted net income from continuing operations before income taxes is broken out between the Successor and Predecessor periods and defined in Note 6. Segment Results of the Condensed Consolidated Financial Statements included in Form 10-Q for Endo, Inc., filed on August 29, 2024.



# Endo has a strong platform to drive growth and create value



## Durable XIAFLEX® Pipeline in a Product Platform

Growing on-market indications and attractive future indications with durable intellectual property estate




## Injectable Solutions Growth Platform

Innovative pipeline of > 50 projects & acute care capabilities with potential to generate sustainable future revenue growth



## Unencumbered Balance Sheet & Strong Cash Flow

Meaningfully improved balance sheet and cash generative business enables growth investments








## Proven and Scalable Capabilities

Commercial expertise, product development know-how, and modernized manufacturing

# Branded Pharmaceuticals: Durable XIAFLEX platform & extensive specialty product expertise

## BUSINESS OVERVIEW & CAPABILITIES

	KEY PRODUCTS	REVENUE
Specialty	<p><b>Specialty Products</b></p>   	<p><b>2023: \$859M</b> <b>1H24: \$426M</b></p>
Legacy	<p><b>Legacy Products</b></p>  	

- **Differentiated and durable portfolio** of specialty urology, orthopedic and endocrinology products anchored by XIAFLEX® for Peyronie’s Disease (urology) and Dupuytren’s Contracture (orthopedics)
- **Strong commercial capabilities** with **extensive Specialty product distribution network** and sales force reach
- **Ongoing commercial and R&D investment** expected to drive Specialty growth
- Diverse set of **Legacy products** across multiple therapeutic areas that require **minimal promotional spend** and other direct costs and **generate strong free cash flow**

# XIAFLEX<sup>®</sup> On-market Growth Strategy

**XPD**

*XIAFLEX is **only nonsurgical treatment option** for patients with Peyronie's Disease*



## Strategies to Grow XPD

- 1 Drive diagnosis & treatment requests through **DTC advertising**
- 2 Increase prescribing breadth and depth through an **improved HCP learning experience**
- 3 Enhance the XIAFLEX experience by leveraging Endo Advantage and **driving commitment to the full XIAFLEX cycle**

**XDC**

*XIAFLEX is **the only nonsurgical treatment option** for patients with Dupuytren's contracture*



## Strategies to Grow XDC

- 1 Motivate patients to effectively advocate for XIAFLEX through **DTC campaigns**
- 2 Inspire fellows and new users to make XIAFLEX their **preferred treatment strategy**
- 3 Advance current injectors to use XIAFLEX as their **first-line treatment in PIP joint**
- 4 **Proactively educate HCPs** and office staff to operationalize XIAFLEX

DEFINITIONS: DC – Dupuytren's Contracture, XDC – XIAFLEX for Dupuytren's Contracture, PIP – proximal interphalangeal joints

# Progressing XIAFLEX<sup>®</sup> development pipeline

## Current Development Programs

Indication	Pre-clinical	Phase I	Phase 2	Phase 3	Target Launch	Patients Under Treatment	Condition Information
<b>Plantar Fibromatosis</b>					<b>2027</b>	~200,000	<ul style="list-style-type: none"> <li>• Painful condition caused by collagen nodules of the plantar surface of the foot</li> <li>• Phase 3 initiated Q4'23</li> </ul>
<b>Plantar Fasciitis</b>					<b>2029</b>	~415,000	<ul style="list-style-type: none"> <li>• Trauma and damage of plantar fascia causing heel pain and loss of mobility</li> <li>• Phase 2 recruitment completed Q2'24, ahead of schedule. Top-line readout expected late '24</li> </ul>
<b>Arthrofibrosis of the Knee post Knee Arthroplasty</b>					<b>&gt;2030</b>	> 60,000	<ul style="list-style-type: none"> <li>• Limited mobility 4-6 weeks post total knee replacement from collagen scar tissue build-up</li> <li>• IND submission targeted for 1H 2025</li> </ul>
<b>Multiple Others</b>							<ul style="list-style-type: none"> <li>• Multiple programs in pre-clinical stage primarily in orthopedic care and other therapeutic areas</li> </ul>

# XIAFLEX<sup>®</sup> is Anchored by a Durable IP Estate

## Protected by robust patent estate

- Current patent estate not limited by indication extends through late-2030's
- Method of use patents on future indications expected to extend through early-2040's & beyond

**Competitor development of a non-recombinant biosimilar utilizing Endo's cell line would be challenging as the company holds it physically under lock and key.**

## Competitor development of recombinant-biosimilar requires extensive investment and time

- Enzyme-based products, like XIAFLEX<sup>®</sup>, work locally, preventing PK assessment. Clinical studies required to demonstrate safety & potency. Requires complex formulation, manufacturing and analytical capabilities
- Not aware of any approved or filed collagenase or enzyme-based biosimilar products in U.S.



*Illustrative recombinant-biosimilar development estimate based upon a product which is locally acting for which PK assessment is not possible to demonstrate similarity.*

# Sterile Injectables:

## Growing pipeline and scalable acute care capabilities

### BUSINESS OVERVIEW & CAPABILITIES

Injectable Solutions

- **Broad portfolio of ~40 on-market** hospital-based products for critical care and testing, maternal health and anesthesia
- **Robust pipeline of > 50 projects** with >60% ready-to-use (RTU) and other differentiated products
- **Scalable** acute care development and commercial capabilities with modernized manufacturing
- **Collaborative engagement** with hospitals and healthcare systems to reduce complexity and develop innovations that add value

### KEY PRODUCTS

**~40 products including:**

**Adrenalin®**  
(epinephrine injection, USP)


**VASOSTRICT®**  
(vasopressin injection, USP)

### REVENUE

**2023: \$430M**  
**1H24: \$189M**

# Sterile Injectable New Product Pipeline

## Sterile Injectable Product Pipeline <sup>(1)</sup>



■ SI Development ■ SI Filed


(1) Pipeline data as of July 31, 2024

**3-4** Planned 2024 product launches

**5** Sterile projects added to the pipeline YTD'24

**28** Sterile projects added to the pipeline since Q1'22

**~60%** Ready to Use (RTU) and differentiated products in SI pipeline



# Established Businesses:

## Stable cash flows and targeted investments

### BUSINESS OVERVIEW & CAPABILITIES

		KEY PRODUCTS	REVENUE
<b>Generics</b>	<ul style="list-style-type: none"> <li>Broad portfolio of commercial products across multiple dosage forms</li> <li>Discrete portfolio of planned new product launches</li> <li>Commercial expertise and optimized manufacturing network and overall cost structure</li> </ul>	~85 Products	<b>2023: \$650M</b>  <b>1H24: \$214M</b>
<b>International</b>	<ul style="list-style-type: none"> <li>Highly scalable, asset-light business model</li> <li>Broad portfolio of new product launches and mature products</li> <li>Expanding portfolio across multiple therapeutic areas via Business Development &amp; Licensing</li> </ul>	~40 Products	<b>2023: \$73M</b>  <b>1H24: \$38M</b>



# Endo has a strong platform to drive growth and create value



## Durable XIAFLEX® Pipeline in a Product Platform

Growing on-market indications and attractive future indications with durable intellectual property estate




## Injectable Solutions Growth Platform

Innovative pipeline of > 50 projects & acute care capabilities with potential to generate sustainable future revenue growth



## Unencumbered Balance Sheet & Strong Cash Flow

Meaningfully improved balance sheet and cash generative business enables growth investments



## Proven and Scalable Capabilities

Commercial expertise, product development know-how, and modernized manufacturing



# Second Quarter Results

---

# Q2 2024 Financial Results

<i>\$ millions</i>	Q2 2024 (Combined) <sup>[c]</sup>	Q2 2023
Branded Pharmaceuticals	\$225	\$212
Sterile Injectables	\$ 91	\$137
Generic Pharmaceuticals	\$110	\$179
International Pharmaceuticals	\$21	\$19
<b>Total Revenues, Net</b>	<b>\$447</b>	<b>\$547</b>
<b>Adjusted Gross Margin % <sup>[a]</sup></b>	<b>69 %</b>	<b>69 %</b>
<b>Adjusted Operating Expenses <sup>[a][b]</sup></b>	<b>\$147</b>	<b>\$147</b>
<b>Adjusted EBITDA <sup>[a]</sup></b>	<b>\$176</b>	<b>\$243</b>
<b>Adjusted Net Income <sup>[a]</sup></b>	<b>\$105</b>	<b>\$231</b>


[a] Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP metric are included herein.

[b] Total operating expenses is calculated as the total of: (i) Selling, general and administrative; (ii) Research and development; (iii) Acquired in-process research and development; (iv) Litigation-related and other contingencies, net;

[c] Refer to slide 21 for calculation of this value.

# Q2 2024 Revenue (\$ million)

## Branded Pharmaceuticals



### XIAFLEX

XIAFLEX<sup>®</sup> revenues increased in-line with expectations primarily due to higher average net selling price and underlying demand. Volume increased 8% compared to Q1'24 and decreased slightly compared to Q2'23 due to changes in channel inventory.

### Non-XIAFLEX Specialty Products (includes SUPPRELIN<sup>®</sup> LA and Other Specialty)

The decrease in Specialty Products revenues was primarily due to decreased SUPPRELIN<sup>®</sup> LA revenues, primarily driven by lower volumes, and lower NASCOBAL<sup>®</sup> Nasal Spray revenues due to generic competition.


### Established Products

Established Products revenues increased primarily due to \$10 million in non-recurring, non-cash adjustments in both Q2'24 and Q2'23 related to previously discontinued products as well as increased revenues related to products that experienced temporary supply disruptions in 2023.

[a] Q2 2024 revenue growth was ~4% after excluding the impact of a \$4M vial wastage rebate reserve in Q2 2023 that was reversed in Q4 2023 following application of final rebate determination.


# Q2 2024 Revenue (\$ million)

## Sterile Injectables




Sterile Injectables revenues decreased 34% primarily due to non-recurring settlement payment in 2023 and competitive pressures in 2024, partially offset by incremental revenues in 2024 from 2023 new product launches.

## Generic Pharmaceuticals



Generic revenues decreased 38% primarily due to increased competitive pressure across multiple products, including varenicline tablets and dexlansoprazole delayed release capsules, partially offset by increased revenues from Lidocaine patch.

## International Pharmaceuticals



International revenues increased 10% primarily due to increased volumes across multiple products.

# Q2 2024 Financial Results

<i>\$ millions</i>	Q2 2024 (Successor)	Q2 2024 (Predecessor)	Q2 2024 (Combined) <sup>[a]</sup>	Q2 2023
Branded Pharmaceuticals	\$146	\$79	\$225	\$212
Sterile Injectables	\$ 56	\$ 34	\$ 90	\$137
Generic Pharmaceuticals	\$ 70	\$ 40	\$110	\$179
International Pharmaceuticals	\$ 12	\$ 9	\$ 21	\$ 19
<b>Total Revenues, net</b>	<b>\$ 284</b>	<b>\$ 162</b>	<b>\$ 446</b>	<b>\$ 547</b>
<b>Adjusted Gross Margin %</b> <sup>[c]</sup>	<b>67%</b>	<b>72%</b>	<b>69%</b>	<b>69%</b>
<b>Adjusted Operating Expenses</b> <sup>[b] [c]</sup>	<b>\$ 113</b>	<b>\$ 34</b>	<b>\$ 147</b>	<b>\$ 147</b>
<b>Adjusted EBITDA</b> <sup>[c]</sup>	<b>\$ 90</b>	<b>\$ 86</b>	<b>\$ 176</b>	<b>\$ 243</b>
<b>Adjusted Net Income</b> <sup>[c]</sup>	<b>\$ 28</b>	<b>\$ 77</b>	<b>\$ 105</b>	<b>\$ 231</b>

[a] As required by GAAP, due to the application of Fresh Start Accounting, results for the quarter must be presented separately for the predecessor period from April 1, 2024 through April 23, 2024 (the “Predecessor” period) and the successor three months ended June 30, 2024 (the “Successor” period). However, to facilitate comparison of our operating results against the relevant prior periods the Company has combined the results of the Predecessor and Successor periods as non-GAAP measures (“combined” results).

[b] Total operating expenses is calculated as the total of: (i) Selling, general and administrative; (ii) Research and development; (iii) Acquired in-process research and development; (iv) Litigation-related and other contingencies, net; (v) Asset impairment charges; and (vi) Acquisition related and integration items, net.

[c] Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP metric are included herein.

# Q2 2024 Non-GAAP Reconciliations – Adjusted EBITDA

The following table provides a reconciliation of Net (loss) income (GAAP) to Adjusted EBITDA (non-GAAP):

\$ 000s	Successor	Predecessor (a)	
	Three Months Ended June 30, 2024	Period From April 1, 2024 through April 23, 2024	Three Months Ended June 30, 2023
<b>Net (loss) income (GAAP)</b>	\$ (148,776)	\$ 6,527,548	\$ 23,438
Income tax (benefit) expense, net	(63,981)	50,629	10,279
Interest expense (income), net	44,669	(3)	120
Depreciation and amortization	60,352	18,030	\$ 77,130
<b>EBITDA (non-GAAP)</b>	\$ (107,736)	\$ 6,596,204	\$ 110,967
Asset impairment charges	—	1,799	—
Acquisition & Divestitures	191,857	(817)	365
Restructuring or similar transactions	5,324	—	14,281
Reorganization items, net	—	(6,328,145)	84,267
Other	246	282	32,964
Discontinued Operations	—	(183,234)	573
<b>Adjusted EBITDA (non-GAAP)</b>	\$ 89,691	\$ 86,089	\$ 243,417

(a) Certain prior period non-GAAP adjustments have been reclassified to conform to the current period presentation.

# Q2 2024 Non-GAAP Reconciliations – Adjusted Net Income

The following table provides a reconciliation of Net (Loss) income (GAAP) to Adjusted Net Income (non-GAAP) (in thousands):

\$ 000s	Successor	Predecessor (a)	
	Three Months Ended June 30, 2024	Period From April 1, 2024 through April 23, 2024	Three Months Ended June 30, 2023
<b>Net (Loss) income (GAAP)</b>	\$ (148,776)	\$ 6,527,548	\$ 23,438
<b>Non-GAAP adjustments:</b>			
Asset impairment charges	—	1,799	—
Acquisition & Divestitures	240,938	14,264	64,915
Restructuring or similar transactions	5,324	1	14,281
Reorganization items, net	—	(6,328,145)	84,267
Other	246	32	34,582
Tax adjustments	(69,610)	44,307	8,649
Discontinued Operations	—	(183,234)	573
<b>Adjusted Net Income (non-GAAP)</b>	<b>\$ 28,122</b>	<b>\$ 76,572</b>	<b>\$ 230,705</b>

(a) Certain prior period non-GAAP adjustments have been reclassified to conform to the current period presentation.



# Q2 2024 Non-GAAP Reconciliations – Select Other Income Statement Data

The following tables provide detailed reconciliations of select other income statement data between the GAAP and non-GAAP measure (in thousands):

\$ 000s	Three Months Ended June 30, 2024 (Successor)						
	Cost of revenues	Gross profit (a)	Gross margin (a)	Total operating expenses (b)	Reorganization items, net	Other expense, net	Income tax (benefit) expense
<b>Reported (GAAP)</b>	\$ 333,695	\$ (49,532)	(17)%	\$ 118,310	\$ —	\$ 246	\$ (63,981)
<b>Items impacting comparability:</b>							
Acquisition & Divestitures (3)	(241,068)	241,068		130	—	—	—
Restructuring or similar transactions (4)	(7)	7		(5,317)	—	—	—
Other (6)	—	—		—	—	(246)	—
Tax adjustments (7)	—	—		—	—	—	69,610
<b>Non-GAAP</b>	\$ 92,620	\$ 191,543	67 %	\$ 113,123	\$ —	\$ —	\$ 5,629

\$ 000s	Period From April 1, 2024 through April 23, 2024 (Predecessor)						
	Cost of revenues	Gross profit (a)	Gross margin (a)	Total operating expenses (b)	Reorganization items, net	Other (income) expense, net	Income tax expense
<b>Reported (GAAP)</b>	\$ 60,539	\$ 101,928	63 %	\$ 35,624	\$ (6,328,145)	\$ (492)	\$ 50,629
<b>Items impacting comparability:</b>							
Asset impairment charges	—	—		(1,799)	—	—	—
Acquisition & Divestitures	(15,081)	15,081		818	—	—	—
Restructuring or similar transactions	(1)	1		—	—	—	—
Reorganization items, net	—	—		—	6,328,145	—	—
Other	—	—		(778)	—	746	—
Tax adjustments	—	—		—	—	—	(44,309)
<b>Non-GAAP</b>	\$ 45,457	\$ 117,010	72 %	\$ 33,865	\$ —	\$ 254	\$ 6,320

# Q2 2024 Non-GAAP Reconciliations – Select Other Income Statement Data (cont'd)

The following tables provide detailed reconciliations of select other income statement data between the GAAP and non-GAAP measure (in thousands):

\$ 000s	Three Months Ended June 30, 2023 (c)						
	Cost of revenues	Gross profit (a)	Gross margin (a)	Total operating expenses (b)	Reorganization items, net	Other expense (income), net	Income tax expense
<b>Reported (GAAP)</b>	\$ 233,852	\$ 313,000	57 %	\$ 194,144	\$ 84,267	\$ 299	\$ 10,279
<b>Items impacting comparability:</b>							
Acquisition & Divestitures	(64,550)	64,550		(365)	—	—	—
Restructuring or similar transactions	(489)	488		(13,793)	—	—	—
Reorganization items, net	—	—		—	(84,267)	—	—
Other	—	—		(32,660)	—	(1,922)	—
Tax adjustments	—	—		—	—	—	(8,649)
<b>Non-GAAP</b>	\$ 168.813	\$ 378.038	69 %	\$ 147.326	\$ —	\$ (1.623)	\$ 1.630

- (a) Gross profit is calculated as total revenues less cost of revenues. Gross margin is calculated as gross profit divided by total revenues. Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.
- (b) Total operating expenses is calculated as the total of: (i) Selling, general and administrative; (ii) Research and development; (iii) Acquired in-process research and development; (iv) Litigation-related and other contingencies, net; (v) Asset impairment charges; and (vi) Acquisition related and integration items, net.
- (c) Certain prior period non-GAAP adjustments have been reclassified to conform to the current period presentation.



# Appendix



# Recently Launched DTC Campaign Emboldens DC Patients

## Helping Patients Take Charge of Their DC Treatment Options



## Call to Action: 5 Simple Reminders

- 1 I don't want surgery for my contracture
- 2 I don't want to wait for my contracture to get worse
- 3 I want treatment with minimal downtime
- 4 I want a non-surgical treatment
- 5 If non-surgical treatment isn't offered, I will get a second opinion

## Launched June 2024

- TV – National broadcast, streaming services, and online
- Full digital media ecosystem – social media, digital, and search advertising

## It's in *your* hands

***Be informed. Assert yourself. Don't settle.***

